pharma · Anal Neoplasm · Lassa Fever · INO
INOVIO Pharmaceuticals
INOVIO PHARMACEUTICALS, INC.
INOVIO Pharmaceuticals is a pharma organization headquartered in Plymouth Meeting, USA. It trades on NYSE under ticker INO. Primary therapeutic focus areas include Anal Neoplasm, Lassa Fever, Prostate Cancer, Chronic Hep
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US HQ
203 Employees
Public company Type
INO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US
- Employees
- 203
- Programs
- 46
- Drugs
- 8
- Patents
- 75
2mg INO-5150 and electroporation device CELLECTRA®-5P
Phase 1 · mab · Prostate Cancer
2mg INO-5150 and electroporation device CELLECTRA®-5P for Prostate Cancer is a Phase 1 program (mab) at INOVIO PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Internal code PCa-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- INOVIO PHARMACEUTICALS, INC.
- Phase
- Phase 1
- Modality
- mab
- Indication
- Prostate Cancer
- Status
- completed
- Trials
- 1